Antibody-drug conjugate (ADC) technology is poised to remain under the spotlight and become a main global trend that will lead anticancer drug development in the next several years.
In South Korea, meanwhile, ADC players are trying to build an ecosystem amid an “imbalance” in the demand and supply of associated technologies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?